A trial looking at pertuzumab and docetaxel for advanced cancer (BO17021)

Cancer type:

All cancer types




Phase 1

This trial looked at pertuzumab (also called Omnitarg) and docetaxel for advanced cancer.

Pertuzumab is a monoclonal antibody. Monoclonal antibodies are a type of biological therapy. They look for specific proteins on the surface of cells. Pertuzumab looks for a protein called HER2, which is made by some cancers.

Docetaxel (Taxotere) is a chemotherapy drug that was already licensed in the UK to treat cancers such as breast, prostate, stomach, bladder and ovarian cancer.

Doctors hoped that the combination of pertuzumab and docetaxel would be useful for treating advanced solid tumours. A solid tumour is any cancer except lymphoma or leukaemia.

The aims of the trial were to find out

  • How well the combination of pertuzumab and docetaxel worked
  • The best dose of docetaxel to have with pertuzumab
  • What the side effects were

Summary of results

The researchers found the best doses to safely give docetaxel and pertuzumab together. They found that this combination of drugs helped some people with advanced cancer.

The trial recruited 19 people. The first 3 people had a low dose of docetaxel and a single dose of pertuzumab. As none of these people had bad side effects, the next group of patients had a higher dose of docetaxel. By slowly increasing the dose for each group of people, the researchers found the best dose of docetaxel to give with pertuzumab. Then they changed the dose of pertuzumab to find the best dose of that drug to have at the same time as docetaxel without causing too many side effects.

The side effects that some people did have with the combination of these drugs included

The trial team also found that

  • In 14 people, the cancer stopped growing after 2 cycles of treatment – researchers call this stable disease Open a glossary item
  • 9 people still had stable disease after 4 cycles of treatment
  • In 1 person the cancer got smaller after 4 cycles of treatment – researchers call this a partial response Open a glossary item

As this trial found the doses at which it is safe to have the 2 drugs together, the researchers suggested there should be more trials to see how well this treatment works for different cancers.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Johann de Bono

Supported by


If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 371

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think